Posts by: Marta Figueiredo PhD

Marta Figueiredo PhD

Marta Figueiredo holds a master’s in evolutionary and developmental biology and a PhD in biomedical sciences from the University of Lisbon, Portugal. Her research is focused on the role of several signaling pathways in thymus and parathyroid glands embryonic development.

March 26, 2021March 29, 2021

Haegarda Available for Eligible Patients in Canada Starting April 6

News

Haegarda, CSL Behring’s preventive treatment for hereditary angioedema (HAE) attacks, will be available to eligible HAE patients across Canada starting on April 6. The availability announcement was issued by Canadian ... Read more

March 22, 2021March 22, 2021

Intellia Seeks to Advance Its Gene-editing Therapy to Human Trials

News

Intellia Therapeutics is advancing clinical manufacturing activities to support its plans to file regulatory applications for first-in-human clinical trials of NTLA-2002, its experimental gene-editing therapy for hereditary angioedema (HAE). The submissions ... Read more

March 1, 2021March 1, 2021

Orladeyo Recommended in EU as 1st Oral Treatment to Prevent HAE Attacks

News

BioCryst Pharmaceuticals’ Orladeyo (berotralstat) has been recommended for approval in the European Union as the first oral therapy for preventing swelling attacks in people with hereditary angioedema (HAE), ages 12 ... Read more

February 18, 2021February 18, 2021

Eurordis Survey: Healthcare Experience Worse for Rare Disease Patients

News, syndicated

People with rare disorders have a worse healthcare experience than those affected by chronic diseases, according to the results of an international survey conducted by Eurordis-Rare Diseases Europe. Indeed, rare ... Read more

November 23, 2020November 23, 2020

Takhzyro Safely Prevents HAE Attacks Over Long Term, Extension Study Shows

News

Takeda’s Takhzyro (lanadelumab) continues to safely prevent and reduce the frequency of swelling attacks in people with hereditary angioedema (HAE), according to 2.5 years of data from the HELP open-label ... Read more

November 20, 2020November 23, 2020

Survey Finds COVID-19 Disrupted Care, Well-Being of Rare Disease Patients in Europe

News, syndicated

The first wave of COVID-19 in Europe severely disrupted access to care and raised stress and anxiety in people with rare diseases, negatively affecting their health and well-being, according to a ... Read more

November 9, 2020November 9, 2020

Berotralstat Available to Eligible Patients in UK Through Early Access Program

News

Berotralstat — an oral therapy by BioCryst Pharmaceuticals for preventing swelling attacks in people with hereditary angioedema (HAE) — will be available to patients, 12 and older, in the U.K. through ... Read more

July 24, 2020July 24, 2020

More Research Needed on Pregnancy-related HAE Attacks, Case Report Shows

News

More insight and study is needed into the symptoms, proper management, and potential complications of pregnancy-related hereditary angioedema (HAE) attacks, according to a case report of a woman who is ... Read more

March 25, 2020March 25, 2020

Berotralstat Lowers Rate of HAE Attacks and Possibly Their Severity, Trial Reports

News

Preventive treatment with berotralstat (BCX7353) significantly lowered the number of swelling attacks — including those needing treatment — and the rates of standard on-demand therapy use in people with hereditary angioedema ... Read more

January 3, 2019January 8, 2019

Simple Diagnostic Test for Hereditary Angioedema Detects Mutations Missed by Current Methods

News, Recently Published

Researchers have developed a more cost-effective supporting diagnostic test for hereditary angioedema (HAE) to detect genetic changes that are otherwise missed by current standard methods. The study, “Gene mapping strategy for Alu ... Read more